{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:21:07Z","timestamp":1790198467059,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Swedish Cancer Society","award":["150767"],"award-info":[{"award-number":["150767"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1245\/s10434-019-07452-2","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T22:00:51Z","timestamp":1569880851000},"page":"293-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC"],"prefix":"10.1245","volume":"27","author":[{"given":"Wilhelm","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Cashin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Ghanipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexei","family":"Terman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"Birgisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"7452_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ejso.2014.06.006","volume":"40","author":"D Elias","year":"2014","unstructured":"Elias D, Mariani A, Cloutier AS, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014;40:1467\u201373.","journal-title":"Eur J Surg Oncol"},{"key":"7452_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/jso.23446","volume":"109","author":"JD Rivard","year":"2014","unstructured":"Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? J Surg Oncol. 2014;109:104\u20139","journal-title":"J Surg Oncol"},{"key":"7452_CR3","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","volume":"21","author":"J Esquivel","year":"2014","unstructured":"Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:4195\u2013201.","journal-title":"Ann Surg Oncol"},{"key":"7452_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1097\/SLA.0000000000001593","volume":"263","author":"R Kwakman","year":"2016","unstructured":"Kwakman R, Schrama AM, van Olmen JP, et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg. 2016;263:1102\u201315","journal-title":"Ann Surg"},{"key":"7452_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ejso.2016.09.012","volume":"43","author":"AH Maciver","year":"2017","unstructured":"Maciver AH, Lee N, Skitzki JJ, Boland PM, Francescutti V. Cytoreduction and hyperthermic intraperitoneal chemotherapy (CS\/HIPEC) in colorectal cancer: evidence-based review of patient selection and treatment algorithms. Eur J Surg Oncol. 2017;43:1028\u201339.","journal-title":"Eur J Surg Oncol"},{"key":"7452_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1144-x","author":"H Birgisson","year":"2015","unstructured":"Birgisson H, Edlund K, Wallin U, et al. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer. 2015. \nhttps:\/\/doi.org\/10.1186\/s12885-015-1144-x\n\n.","journal-title":"BMC Cancer."},{"key":"7452_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.10.006","author":"H Kayhanian","year":"2018","unstructured":"Kayhanian H, Goode E, Sclafani F, et al. Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: a retrospective matched case\u2013control study. Clin Colorectal Cancer. 2018. \nhttps:\/\/doi.org\/10.1016\/j.clcc.2017.10.006\n\n.","journal-title":"Clin Colorectal Cancer."},{"key":"7452_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/jnci\/djt173","volume":"105","author":"P Lochhead","year":"2013","unstructured":"Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151\u20136.","journal-title":"J Natl Cancer Inst."},{"key":"7452_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2014.00050","author":"DE Green","year":"2015","unstructured":"Green DE, Jayakrishnan TT, Hwang M, Pappas SG, Gamblin TC, Turaga KK. Immunohistochemistry\u2014microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin. Front Surg. 2015. \nhttps:\/\/doi.org\/10.3389\/fsurg.2014.00050\n\n.","journal-title":"Front Surg."},{"key":"7452_CR10","doi-asserted-by":"publisher","DOI":"10.3892\/or.2016.5323","author":"K Fujiyoshi","year":"2017","unstructured":"Fujiyoshi K, Yamamoto G, Takahashi A, et al. High concordance rate of KRAS\/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep. 2017. \nhttps:\/\/doi.org\/10.3892\/or.2016.5323\n\n.","journal-title":"Oncol Rep."},{"key":"7452_CR11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","volume":"268","author":"MA Schneider","year":"2018","unstructured":"Schneider MA, Eden J, Pache B, et al. Mutations of RAS\/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268:845\u201353.","journal-title":"Ann Surg"},{"key":"7452_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342.","journal-title":"Ann Surg"},{"key":"7452_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7800-2-3","author":"RL Harmon","year":"2005","unstructured":"Harmon RL, Sugarbaker PH. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol. 2005. \nhttps:\/\/doi.org\/10.1186\/1477-7800-2-3\n\n.","journal-title":"Int Semin Surg Oncol."},{"key":"7452_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"key":"7452_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jmoldx.2015.06.009","volume":"17","author":"LN Moens","year":"2015","unstructured":"Moens LN, Falk-S\u00f6rqvist E, Ljungstr\u00f6m V, Mattsson J, Sundstr\u00f6m M, La Fleur L, Mathot L, Micke P, Nilsson M, Botling J. HaloPlex targeted resequencing for mutation detection in clinical formalin-fixed, paraffin-embedded tumor samples. J Mol Diagn. 2015;17:729\u201339.","journal-title":"J Mol Diagn"},{"key":"7452_CR16","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1186\/1471-2407-10-660","volume":"10","author":"M Sundstr\u00f6m","year":"2010","unstructured":"Sundstr\u00f6m\u00a0M, Edlund K, Lindell M, Glimelius B, Birgisson H, Micke P, Botling J. KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660.","journal-title":"BMC Cancer"},{"key":"7452_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00534-012-0531-9","volume":"20","author":"Y Umeda","year":"2013","unstructured":"Umeda Y, Nagasaka T, Mori Y, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci. 2013;20:223\u201333.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"7452_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gutjnl-2012-302423","volume":"62","author":"S Tian","year":"2013","unstructured":"Tian S, Simon I, Moreno V, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62:540\u20139.","journal-title":"Gut"},{"key":"7452_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.critrevonc.2015.12.015","volume":"99","author":"F Passiglia","year":"2016","unstructured":"Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;99:150\u20137.","journal-title":"Crit Rev Oncol Hematol"},{"key":"7452_CR20","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.1245\/s10434-016-5361-6","volume":"23","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Margonis GA, Wilson A, et al. Prognostic implication of KRAS status after hepatectomy for colorectal liver metastases varies according to primary colorectal tumor location. Ann Surg Oncol. 2016;23:3736\u201343.","journal-title":"Ann Surg Oncol"},{"key":"7452_CR21","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"7452_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8(1):48\u201356.","journal-title":"Ther Adv Med Oncol."},{"issue":"3","key":"7452_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/PPO.0000000000000189","volume":"22","author":"K Korphaisarn","year":"2016","unstructured":"Korphaisarn K, Kopetz S. BRAF-directed therapy in metastatic colorectal cancer. Cancer J. 2016;22(3):175\u20138.","journal-title":"Cancer J."},{"key":"7452_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jamasurg.2015.0313","volume":"150","author":"GA Margonis","year":"2015","unstructured":"Margonis GA, Kim Y, Spolverato G, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg. 2015;150:722\u20139.","journal-title":"JAMA Surg"},{"key":"7452_CR25","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1245\/s10434-015-4587-z","volume":"22","author":"GA Margonis","year":"2015","unstructured":"Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM. Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2015;22:4158\u201365.","journal-title":"Ann Surg Oncol"},{"key":"7452_CR26","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1002\/cncr.28954","volume":"120","author":"NE Kemeny","year":"2014","unstructured":"Kemeny NE, Chou JF, Capanu M, et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer. 2014;120:3965\u201371.","journal-title":"Cancer"},{"key":"7452_CR27","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","volume":"66","author":"A Lievre","year":"2006","unstructured":"Lievre A, Bachet JB, Le Corre B, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992\u20135.","journal-title":"Cancer Res."},{"key":"7452_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jso.21169","volume":"99","author":"JO Pelz","year":"2009","unstructured":"Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9\u201315.","journal-title":"J Surg Oncol"},{"key":"7452_CR29","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/SLA.0b013e318254f281","volume":"256","author":"PH Cashin","year":"2012","unstructured":"Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg. 2012;256:1078\u201383.","journal-title":"Ann Surg"},{"key":"7452_CR30","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1245\/s10434-017-6042-9","volume":"24","author":"K Demey","year":"2017","unstructured":"Demey K, Wolthuis A, de Buck van Overstraeten A, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017; 24: 3604\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"7452_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.amjsurg.2016.03.008","volume":"213","author":"D Massalou","year":"2017","unstructured":"Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213(2):377\u201387.","journal-title":"Am J Surg."},{"issue":"23","key":"7452_CR32","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","volume":"35","author":"JC Jones","year":"2017","unstructured":"Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J Clin Oncol. 2017;35(23):2624\u201330","journal-title":"J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07452-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07452-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:09:39Z","timestamp":1601320179000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07452-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["7452"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07452-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]},"assertion":[{"value":"22 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has any conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}